International Journal of Cancer
15 April 2016 Volume 138, Issue 8
http://onlinelibrary.wiley.com/doi/10.1002/ijc.v138.8/issuetoc
Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

.
Research Article
Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study
Eva Herweijer1,*, Karin Sundström2, Alexander Ploner1, Ingrid Uhnoo3, Pär Sparén1 and
Lisen Arnheim-Dahlström1
DOI: 10.1002/ijc.30035
Abstract
Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia (CIN) grades 2/3 or worse (CIN2+/CIN3+) including adenocarcinoma in situ or worse. The aim of this study was to quantify the effect of quadrivalent HPV (qHPV) vaccination on incidence of CIN2+ and CIN3+. A nationwide cohort of girls and young women resident in Sweden 2006-2013 and aged 13-29 (n=1,333,691) was followed for vaccination and histologically confirmed high-grade cervical lesions. Data were collected using the Swedish nationwide healthcare registers. Poisson regression was used to calculate incidence rate ratios (IRRs) and vaccine effectiveness [(1-IRR)x100%] comparing fully vaccinated with unvaccinated individuals. IRRs were adjusted for attained age and parental education, and stratified on vaccination initiation age. Effectiveness against CIN2+ was 75% (IRR=0.25, 95%CI=0.18-0.35) for those initiating vaccination before age 17, and 46% (IRR=0.54, 95%CI=0.46-0.64) and 22% (IRR=0.78, 95%CI=0.65-0.93) for those initiating vaccination at ages 17-19, and at ages 20-29, respectively. Vaccine effectiveness against CIN3+ was similar to vaccine effectiveness against CIN2+. Results were robust for both women participating to the organized screening program and for women at pre-screening ages. We show high effectiveness of qHPV vaccination on CIN2+ and CIN3+ lesions, with greater effectiveness observed in girls younger at vaccination initiation. Continued monitoring of impact of HPV vaccination in the population is needed in order to evaluate both long-term vaccine effectiveness and to evaluate whether the vaccination program achieves anticipated effects in prevention of invasive cervical cancer.